Neuropathic Pain | Access and Reimbursement | EU5 | 2016
The rising prevalence in EU5 markets of neuropathic pain associated with multiple conditions represents commercial opportunities for drug manufacturers. However, a growing generic presence among multiple drug classes, particularly with generic availability in 2017 of key antiepileptic drugs prescribed for neuropathic pain will result in increasing market access challenges for branded therapies. New products in this space will struggle to clinically differentiate themselves from current therapies, particularly to market access authorities, but the potential patient share could be considerable for new analgesics that convincingly demonstrate efficacy and/or tolerability benefits over existing therapies and secure favorable pricing and reimbursement terms.
